Soquelitinib is under clinical development by Corvus Pharmaceuticals and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase I drugs for Atopic Dermatitis (Atopic Eczema) have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Soquelitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Soquelitinib overview

Soquelitinib (CPI-818) is under development for the treatment of acute and chronic asthma, systemic sclerosis, cutaneous T-cell lymphoma, T-cell leukemia, angioimmunoblastic T-cell lymphoma, pulmonary fibrosis, psoriasis, systemic lupus erythematosus, colon cancer, renal cell cancer, B cell cancers, atopic dermatitis (Inflammatory), unspecified immunological disorders, peripheral T-cell lymphomas, autoimmune lympho-proliferative disease, acute graft versus host disease in patients receiving bone marrow transplantation, other auto immune diseases, allergies and solid tumors including non-small cell lung cancer, renal cell carcinoma (RCC), melanoma. It is administered through oral route in the form of capsule. It acts by targeting tyrosine-protein kinase ITK.

Corvus Pharmaceuticals overview

Corvus Pharmaceuticals (Corvus Pharma) is a clinical-stage biopharmaceutical company. It operates in the development and commercialization of immuno-oncology therapies that are used for treating cancer. It offers pipeline products such as CPI-818, A2A inhibitor, ciforadenant (CPI-444), mupadolimab (CPI-006) and others. Corvus Pharma’s product CPI-444 is an oral small molecule antagonist that blocks the A2A receptor. The company also develops a product candidate an anti-CD73 monoclonal antibody that inhibits the production of adenosine produced by the tumor cells. Corvus Pharma’s product pipeline also includes adenosine A2B receptor antagonists ITK inhibitors and myeloid cell suppression. The company operates in the US and the Cayman Islands. Corvus Pharma is headquartered in Burlingame, California, US.

For a complete picture of Soquelitinib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.